The cost effectiveness of human papillomavirus vaccines: A systematic review

Drugs

Volumn 72, Issue 5, 2012, Pages 715-743

  Seto, Katherine ^a   Marra, Fawziah ^a,b   Raymakers, Adam ^a   Marra, Carlo A ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c PROVIDENCE HEALTH CARE RESEARCH INSTITUTE   (Canada)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Cost effectiveness; Decision making; Human papillomavirus infections; Human papillomavirus vaccine; Sexually transmitted disorders; Willingness to pay

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER SCREENING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH PROGRAM; HUMAN; MALE HOMOSEXUAL; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE;

COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84858768956     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11599470-000000000-00000     Document Type: Review

References (85)

1. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-32 (Pubitemid 46986496)
2. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24 Suppl. 3: S3/11-25
3. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-44
4. Goodman A. Primary vaginal cancer. Surg Oncol Clin N Am 1998; 7: 347-61 (Pubitemid 28208492)
5. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005; 106: 1319-26 (Pubitemid 41668952)
6. Dianzani C, Calvieri S, Pierangeli A, et al. Identification of human papilloma viruses in male dysplastic genital lesions. New Microbiol 2004; 27: 65-9 (Pubitemid 40091029)
7. McKaig RG, Baric RS, Olshan AF. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck 1998; 20: 250-65 (Pubitemid 28169738)
8. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions. HPV-6/11 disease. Vaccine 2006; 24 Suppl. 3: S3/35-41
9. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006; 61: S3-14 (Pubitemid 43880137)
10. Derkay CS, Darrow DH. Recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2006; 115: 1-11 (Pubitemid 43132434)
11. GlaxoSmithKline. Cervarix-: human papillomavirus vaccine types 16 and 18 (recombinant, AS04 adjuvanted) [product monograph; online]. Available from URL: http://www.gsk.ca/english/docs-pdf/product-monographs/Cervarix. pdf [Accessed 2010 Nov 9]
12. Merck Frosst. Gardasil-: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine [product monograph; online]. Available from: http://www.merck.ca/mfcl/en/corporate/products/gardasil.html [Accessed 2010 Nov 9]
13. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65 (Pubitemid 39488060)
14. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55
15. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107: 18-27
16. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-83 (Pubitemid 44172918)
17. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8 (Pubitemid 40590263)
18. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-66 (Pubitemid 44863348)
19. FUTURE I/II Study Group, Dillner J, Kjaer SK, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341: c3493
20. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51 (Pubitemid 35340782)
21. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27
22. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43 (Pubitemid 46740303)
23. Giuliano AR, Palefsky J. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPVrelated genital disease in young men [online]. Available from URL: http://www.eurogin.com/2008/EUROGIN2008- Last MinuteAbstracts.pdf [Accessed 2010 Nov 9]
24. Palefsky JM, Giuliano AR. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men [online]. Available from URL: http://www.eur ogin.com/2008/EUROGIN2008- LastMinuteAbstracts.pdf [Accessed 2010 Nov 9]
25. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-24
26. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005; 23 (11): 1107-22 (Pubitemid 41633402)
27. Fleurence RL, Dixon JM, Milanova TF, et al. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol 2007; 196: 206-12 (Pubitemid 46341227)
28. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the united states. Am J Obstet Gynecol 2008; 198: 500.e1-7
29. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 37-48 (Pubitemid 36110201)
30. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-9 (Pubitemid 37432955)
31. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-15 (Pubitemid 38584984)
32. Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25: 5399-408 (Pubitemid 46977529)
33. Kulasingam S, Connelly L, Conway E, et al. A costeffectiveness analysis of adding a human papillomavirus vaccine to the Australian national cervical cancer screening program. Sex Health 2007; 4: 165-75 (Pubitemid 47339645)
34. Giuliano AR. Human papillomavirus vaccination in males. Gynecol Oncol 2007; 107: S24-6 (Pubitemid 47559076)
35. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191 Suppl. 1: S97-106 (Pubitemid 40144234)
36. Marra F, Cloutier K, Oteng B, et al. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009; 27 (2): 127-47
37. Drummond MF, Richardson WS, O'Brien BJ, et al. Users' guides to the medical literature: XIII. How to use an article on economic analysis of clinical practice. A: are the results of the study valid? Evidence-based medicine working group. JAMA 1997; 277: 1552-7 (Pubitemid 27213306)
38. Ginsberg GM, Fisher M, Ben-Shahar I, et al. Cost-utility analysis of vaccination against HPV in Israel. Vaccine 2007; 25: 6677-91 (Pubitemid 47337133)
39. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008; 115: 947-56 (Pubitemid 351841762)
40. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359: 821-32
41. Kim JJ, Kobus KE, Diaz M, et al. Exploring the costeffectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 2008; 26: 4015-24
42. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769
43. Rogoza RM, Ferko N, Bentley J, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multiregional health economic analysis. Vaccine 2008; 26 Suppl. 5: F46-58
44. Diaz M, Kim JJ, Albero G, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008; 99: 230-8
45. Usher C, Tilson L, Olsen J, et al. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 2008; 26: 5654-61
46. Zechmeister I, Blasio BF, Garnett G, et al. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009; 27: 5133-41
47. Coupé VM, van Ginkel J, de Melker HE, et al. HPV16/18 vaccination to prevent cervical cancer in the Netherlands: model-based cost-effectiveness. Int J Cancer 2009; 124: 970-8
48. Annemans L, Remy V, Oyee J, et al. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009; 27: 231-45
49. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339: b3884
50. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009; 151: 538-45
51. Thiry N, De Laet C, Hulstaert F, et al. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009; 25: 161-70
52. Rogoza RM, Westra TA, Ferko N, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009; 27: 4776-83
53. de Kok IM, van Ballegooijen M, Habbema JD. Costeffectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009; 101: 1083-92
54. Colantonio L, Gomez JA, Demarteau N, et al. Costeffectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009; 27: 5519-29
55. Sinanovic E, Moodley J, Barone MA, et al. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine 2009; 27: 6196-202
56. Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 2009; 40: 503-13
57. Anonychuk AM, Bauch CT, Merid MF, et al. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009; 9: 401
58. Mennini FS, Giorgi Rossi P, Palazzo F, et al. Health and economic impact associated with a quadrivalent HPV vaccine in italy. Gynecol Oncol 2009; 112: 370-6
59. Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010; 20: 213-9
60. Dasbach EJ, Nagy L, Brandtmuller A, et al. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ 2010; 13: 110-8
61. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28: 6858-67
62. Diaz M, de Sanjose S, Ortendahl J, et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 2010; 46: 2973-85
63. Torvinen S, Nieminen P, Lehtinen M, et al. Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. J Med Econ 2010; 13: 284-94
64. Liu PH, Hu FC, Lee PI, et al. Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan. BMC Health Serv Res 2010; 10: 11
65. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010; 26: 183-91
66. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010; 10 (12): 845-52
67. Debicki D, Ferko N, Demarteau N, et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 2008; 26 Suppl. 5: F16-28
68. Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007; 96: 143-50 (Pubitemid 46094653)
69. Goldie SJ, Kim JJ, Kobus K, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007; 25: 6257-70 (Pubitemid 47088030)
70. Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166: 137-50 (Pubitemid 47227293)
71. National Board of Health, Danish Centre for Health Technology Assessment. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV): a health technology assessment. Copenhagen: National Board of Health, Danish Centre for Health Technology Assessment, 2007 [online]. Available from URL: http://www.sst.dk/publ/Publ2007/MTV/HPV/HPV-vaccination-en. pdf [Accessed 2010 Nov 9]
72. Goldhaber-Fiebert JD, Stout NK, Salomon JA, et al. Costeffectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008; 100: 308-20 (Pubitemid 351480523)
73. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 2372-81 (Pubitemid 34493200)
74. Habbema JD, van Oortmarssen GJ, Lubbe JT, et al. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed 1985; 20: 79-93 (Pubitemid 16217562)
75. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151: 1158-71 (Pubitemid 30451948)
76. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, et al. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007; 5: 11
77. Suarez E, Smith JS, Bosch FX, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 2008; 26 Suppl. 5: F29-45
78. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38 (Pubitemid 24013155)
79. Neilson A, Freiesleben de Blasio B. Economic evaluation of the human papillomavirus(HPV): vaccination in Norway. 2007 [online]. Available from URL: http://www.mendeley. com/research/economic-evaluation-human- papillomavirushpvvaccination-norway/[Accessed 2012 Feb 20]
80. Lauer JA, Rö hrich K, Wirth H, et al. PopMod: a longitudinal population model with two interacting disease states. Cost Eff Resour Alloc 2003; 1 (1): 6
81. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41 (Pubitemid 46057835)
82. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007; 97: 1322-8 (Pubitemid 350035812)
83. Elbasha EH, Dasbach EJ, Insinga RP. A multi-type HPV transmission model. Bull Math Biol 2008; 70: 2126-76
84. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-23 (Pubitemid 39458555)
85. Insinga RP, Dasbach EJ, Elbasha EH, et al. Costeffectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic modelbased evaluation. Vaccine 2007; 26: 128-39 (Pubitemid 350218187)